STERIS PLC

STERIS PLC Stock Forecast & Price Prediction

Live STERIS PLC Stock (STE) Price
$227.44

8

Ratings

  • Buy 6
  • Hold 2
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$227.44

P/E Ratio

39.97

Volume Traded Today

$1.3M

Dividend

$0.57

52 Week High/low

248.24/195.47

STERIS PLC Market Cap

$22.27B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $STE ๐Ÿ›‘

Before you buy STE you'll want to see this list of ten stocks that have huge potential. Want to see if STE made the cut? Enter your email below

STE Summary

From what 8 stock analysts predict, the share price for STERIS PLC (STE) might increase by 10.62% in the next year. This is based on a 12-month average estimation for STE. Price targets go from $230 to $265. The majority of stock analysts believe STE is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

STE Analyst Ratings

STERIS PLC has a total of 8 Wall St Analyst ratings. There are 6 buy ratings, 2 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that STERIS PLC will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

STE stock forecast by analyst

These are the latest 20 analyst ratings of STE.

Analyst/Firm

Rating

Price Target

Change

Date

Jason Bednar
Piper Sandler

Overweight

$260

Upgrade

Oct 24, 2024
Brett Fishbin
Keybanc

Overweight

$265

Maintains

Sep 3, 2024
Mike Matson
Needham

Hold


Reiterates

Aug 8, 2024
David Turkaly
JMP Securities

Market Outperform

$265

Reiterates

Aug 7, 2024
Jacob Johnson
Stephens & Co.

Overweight

$260

Reiterates

Aug 7, 2024
David Turkaly
JMP Securities

Market Outperform

$265

Reiterates

Jul 26, 2024
Jason Bednar
Piper Sandler

Neutral

$225

Reiterates

May 10, 2024
Mike Matson
Needham

Hold


Reiterates

May 10, 2024
David Turkaly
JMP Securities

Market Outperform

$265

Reiterates

May 9, 2024
Mike Matson
Needham

Hold


Reiterates

Apr 12, 2024
Jacob Johnson
Stephens & Co.

Overweight

$250

Reiterates

Feb 9, 2024
David Turkaly
JMP Securities

Market Outperform

$265

Reiterates

Feb 8, 2024
Brett Fishbin
Keybanc

Overweight

$253

Initiates

Feb 6, 2024
Patrick Wood
Morgan Stanley

Equal-Weight

$215

Maintains

Dec 4, 2023
David Turkaly
JMP Securities

Market Outperform

$265

Reiterates

Nov 9, 2023
Jason Bednar
Piper Sandler

Neutral

$215

Maintains

Oct 27, 2023
Jason Bednar
Piper Sandler

Neutral

$215

Maintains

Oct 26, 2023
Jacob Johnson
Stephens & Co.

Overweight

$250

Reiterates

Sep 25, 2023
David Turkaly
JMP Securities

Market Outperform

$265

Maintains

Sep 1, 2023
Patrick Wood
Morgan Stanley

Equal-Weight

$225

Maintains

Aug 3, 2023

STE Company Information

What They Do: Provides infection prevention products and services.

Business Model: STERIS plc generates revenue through its three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. It offers a wide range of products, including cleaning chemistries, sterilization equipment, and automated reprocessing systems, along with maintenance and consulting services. The company serves hospitals, healthcare providers, and pharmaceutical manufacturers, ensuring a steady demand for its offerings.

Other Information: Founded in 1985 and headquartered in Mentor, Ohio, STERIS plc operates globally, leveraging its expertise in infection prevention to maintain strong relationships with its clients. The company's diverse product portfolio and integrated service offerings position it well within the healthcare and life sciences sectors.
STE
STERIS PLC (STE)

When did it IPO

1992

Staff Count

18,000

Country

United States

Sector/Industry

Healthcare/Medical Devices

CEO

Mr. Daniel A. Carestio

Market Cap

$22.27B

STERIS PLC (STE) Financial Data

In 2023, STE generated $4.54B in revenue, which was a increase of 7.41% from the previous year. This can be seen as a signal that STE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

N/A

Revenue From 2021

$3.11B

0.00 %
From Previous Year

Revenue From 2022

$4.22B

35.91 %
From Previous Year

Revenue From 2023

$4.54B

7.41 %
From Previous Year
  • Revenue TTM $5.23B
  • Operating Margin TTM 16.9%
  • Gross profit TTM $2.22B
  • Return on assets TTM 5.5%
  • Return on equity TTM 9.0%
  • Profit Margin 7.6%
  • Book Value Per Share 64.32%
  • Market capitalisation $22.27B
  • Revenue for 2021 $3.11B
  • Revenue for 2022 $4.22B
  • Revenue for 2023 $4.54B
  • EPS this year (TTM) $5.65

STERIS PLC (STE) Latest News

News Image

Wed, 30 Oct 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - STERIS plc (NYSE: STE) will pay a quarterly dividend of $0.57 per share on December 19, 2024, to shareholders recorded by November 19, 2024.

Why It Matters - STERIS plc's announcement of a quarterly dividend indicates financial stability and commitment to returning value to shareholders, which can attract investors seeking income-generating stocks.

News Image

Wed, 30 Oct 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Steris (STE) is expected to report strong earnings due to favorable conditions. Investors should prepare for key expectations ahead of the earnings report.

Why It Matters - Steris's potential earnings beat may signal strong financial performance, boosting investor confidence and possibly increasing share price ahead of the report.

News Image

Fri, 01 Nov 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Analysts are evaluating Steris's performance for Q3 2024, focusing on key metrics beyond top and bottom-line estimates to gain insights into the company's business performance.

Why It Matters - Evaluating key metrics beyond estimates provides insights into Steris's operational performance and future growth potential, influencing investment decisions and stock valuations.

News Image

Wed, 23 Oct 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - STERIS plc (NYSE: STE) will host a conference call on November 7, 2024, at 9:00 a.m. ET to discuss its fiscal 2025 Q2 financial results. Details available at www.steris-ir.com.

Why It Matters - STERIS plc's upcoming conference call on fiscal Q2 results may impact stock performance and investor sentiment, providing insights into financial health and future guidance.

News Image

Mon, 21 Oct 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - STERIS is expected to report positive second-quarter fiscal 2025 results due to the normalization of its Healthcare backlog.

Why It Matters - STERIS' improved second-quarter results indicate a recovering healthcare backlog, suggesting potential revenue growth and operational efficiency, positively impacting investor sentiment.

News Image

Wed, 09 Oct 2024

Sentiment - POSITIVE

Source - GuruFocus

Summary - STERIS plc has secured a $1.1 billion revolving credit facility, replacing its prior agreement, effective October 7, 2024, facilitated by JPMorgan Chase Bank.

Why It Matters - STERIS plc's $1.1 billion revolving credit facility enhances liquidity, providing financial flexibility for growth or debt management, which can positively impact stock performance and investor confidence.

...

STE Frequently asked questions

The highest forecasted price for STE is $265 from David Turkaly at JMP Securities.

The lowest forecasted price for STE is $230 from from

The STE analyst ratings consensus are 6 buy ratings, 2 hold ratings, and 0 sell ratings.